Discover more from Courageous Discourse™ with Dr. Peter McCullough & John Leake
Countermeasures for Marburg Virus Disease
Variety of Therapeutics and Vaccines are Considered
By Peter A. McCullough, MD, MPH
Recently former NIAID director Dr. Anthony Fauci stated with certainty there will be another infectious disease crisis “inevitably, there will be another pandemic, whether this next year or decades from now.” In that interview with CNN Jim Acosta, Fauci also doubled-down on public masking and his theory that SARS-CoV-2 arose from nature—both of which know have been completely disproven in published studies and by our own US government agencies.
I found his comments about another crisis worth taking up for the filovirus, Marburg, and the commonly fatal illness—Marburg disease. There have been sporadic outbreaks of Marburg’s disease in sub-Saharan Africa for 50 years. Here is the CDC’s description of the syndrome: “After an incubation period of 2-21 days, symptom onset is sudden and marked by fever, chills, headache, and myalgia. Around the fifth day after the onset of symptoms, a maculopapular rash, most prominent on the trunk (chest, back, stomach), may occur. Nausea, vomiting, chest pain, a sore throat, abdominal pain, and diarrhea may appear. Symptoms become increasingly severe and can include jaundice, inflammation of the pancreas, severe weight loss, delirium, shock, liver failure, massive hemorrhaging, and multi-organ dysfunction.”
With this vignette, I can tell you as a doctor I will refuse to sit in lockdown and wait for a vaccine. In 2020, Kortepeter et al published a paper highlighting potential treatments and future vaccines. Not mentioned is hydroxychloroquine which other papers have proposed as being a useful first empiric approach. Among the immediately available products in the world to consider that are known to be safe—would be hydroxychloroquine and favipiravir, a Japanese antiviral used for influenza and COVID-19. The other strategies shown in table are futuristic genetic agents or products with unacceptable toxicity such as remdesivir. Early therapeutics and high-quality supportive care which is commonly not available in poor African countries hold the promise to reduce mortality for this sporadic illness.
In summary, we need to be looking at papers that give guidance on empiric strategies when and if another crisis develops. The world has concluded we cannot vaccinate our way out of future outbreaks with untested, unsafe genetic vaccines. Hence our focus will be treatment, treatment, treatment.
If you find “Courageous Discourse” enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.
Kortepeter MG, Dierberg K, Shenoy ES, Cieslak TJ; Medical Countermeasures Working Group of the National Ebola Training and Education Center's (NETEC) Special Pathogens Research Network (SPRN). Marburg virus disease: A summary for clinicians. Int J Infect Dis. 2020 Oct;99:233-242. doi: 10.1016/j.ijid.2020.07.042. Epub 2020 Aug 3. PMID: 32758690; PMCID: PMC7397931.